Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
Circulation ; 147(17): 1264-1276, 2023 04 25.
Artigo em Inglês | MEDLINE | ID: mdl-36866664

RESUMO

BACKGROUND: Concerns have been raised about the long-term performance of aortic stent grafts for the treatment of abdominal aortic aneurysms, in particular, unibody stent grafts (eg, Endologix AFX AAA stent grafts). Only limited data sets are available to evaluate the long-term risks related to these devices. The SAFE-AAA Study (Comparison of Unibody and Non-Unibody Endografts for Abdominal Aortic Aneurysm Repair in Medicare Beneficiaries Study) was designed with the Food and Drug Administration to provide a longitudinal assessment of the safety of unibody aortic stent grafts among Medicare beneficiaries. METHODS: The SAFE-AAA Study was a prespecified, retrospective cohort study evaluating whether unibody aortic stent grafts are noninferior to non-unibody aortic stent grafts with respect to the composite primary outcome of aortic reintervention, rupture, and mortality. Procedures were evaluated from August 1, 2011, through December 31, 2017. The primary end point was evaluated through December 31, 2019. Inverse probability weighting was used to account for imbalances in observed characteristics. Sensitivity analyses were used to evaluate the effect of unmeasured confounding, including assessment of the falsification end points heart failure, stroke, and pneumonia. A prespecified subgroup included patients treated from February 22, 2016, through December 31, 2017, corresponding to the market release of the most contemporary unibody aortic stent grafts (Endologix AFX2 AAA stent graft). RESULTS: Of 87 163 patients who underwent aortic stent grafting at 2146 US hospitals, 11 903 (13.7%) received a unibody device. The average age of the total cohort was 77.0±6.7 years, 21.1% were female, 93.5% were White, 90.8% had hypertension, and 35.8% used tobacco. The primary end point occurred in 73.4% of unibody device-treated patients versus 65.0% of non-unibody device-treated patients (hazard ratio, 1.19 [95% CI, 1.15-1.22]; noninferior P value of 1.00; median follow-up, 3.4 years). Falsification end points were negligibly different between groups. In the subgroup treated with contemporary unibody aortic stent grafts, the cumulative incidence of the primary end point occurred in 37.5% of unibody device-treated patients and 32.7% of non-unibody device-treated patients (hazard ratio, 1.06 [95% CI, 0.98-1.14]). CONCLUSIONS: In the SAFE-AAA Study, unibody aortic stent grafts failed to meet noninferiority compared with non-unibody aortic stent grafts with respect to aortic reintervention, rupture, and mortality. These data support the urgency of instituting a prospective longitudinal surveillance program for monitoring safety events related to aortic stent grafts.


Assuntos
Aneurisma da Aorta Abdominal , Implante de Prótese Vascular , Procedimentos Endovasculares , Humanos , Feminino , Idoso , Estados Unidos , Idoso de 80 Anos ou mais , Masculino , Prótese Vascular , Implante de Prótese Vascular/efeitos adversos , Estudos Retrospectivos , Estudos Prospectivos , Resultado do Tratamento , Procedimentos Endovasculares/efeitos adversos , Medicare , Stents , Desenho de Prótese
2.
Sex Transm Dis ; 41(3): 173-9, 2014 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-24521723

RESUMO

BACKGROUND: Trichomonas vaginalis (TV) and bacterial vaginosis (BV) are independently associated with increased risk of vaginal shedding in HIV-positive women. Because these 2 conditions commonly co-occur, this study was undertaken to examine the association between TV/BV co-occurrence and vaginal shedding of HIV-1 RNA. METHODS: HIV-positive women attending outpatient HIV clinics in 3 urban US cities underwent a clinical examination; were screened for TV, BV, Neisseria gonorrhoeae, Chlamydia trachomatis, and vulvovaginal candidiasis; and completed a behavioral survey. Women shedding HIV-1 RNA vaginally (≥50 copies/mL) were compared with women who had an undetectable (<50 copies/mL) vaginal viral load to determine if women who were TV positive and BV positive or had co-occurrence of TV/BV had higher odds of shedding vaginally when compared with women who did not have these conditions. RESULTS: In this sample of 373 HIV-positive women, 43.1% (n = 161) had co-occurrence of TV/BV and 33.2% (n = 124) were shedding HIV-1 RNA vaginally. The odds of shedding HIV vaginally in the presence of TV alone or BV alone and when TV/BV co-occurred were 4.07 (95% confidence interval [CI], 1.78-9.37), 5.65 (95% CI, 2.64-12.01), and 18.63 (95% CI, 6.71-51.72), respectively, when compared with women with no diagnosis of TV or BV, and after adjusting for age, antiretroviral therapy status, and plasma viral load. CONCLUSIONS: T. vaginalis and BV were independently and synergistically related to vaginal shedding of HIV-1 RNA. Screening and prompt treatment of these 2 conditions among HIV-positive women are important not only clinically but for HIV prevention, as well.


Assuntos
Candidíase Vulvovaginal/microbiologia , Infecções por HIV/microbiologia , HIV-1/isolamento & purificação , RNA Viral/metabolismo , Vaginite por Trichomonas/microbiologia , Trichomonas vaginalis/isolamento & purificação , Vaginose Bacteriana/microbiologia , Adulto , Contagem de Linfócito CD4 , Candidíase Vulvovaginal/complicações , Candidíase Vulvovaginal/epidemiologia , Coinfecção , Feminino , Infecções por HIV/epidemiologia , Infecções por HIV/prevenção & controle , Humanos , Prevalência , Comportamento Sexual , Vaginite por Trichomonas/complicações , Vaginite por Trichomonas/epidemiologia , Estados Unidos , População Urbana , Vagina/microbiologia , Descarga Vaginal/microbiologia , Vaginose Bacteriana/complicações , Vaginose Bacteriana/epidemiologia , Carga Viral , Eliminação de Partículas Virais
3.
Sex Transm Infect ; 87(3): 205-8, 2011 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-21278401

RESUMO

OBJECTIVE: Trichomonas vaginalis (TV) is common in HIV+ women, and host factors may play a role in TV treatment outcomes. The purpose of this study was to examine the influence of bacterial vaginosis (BV) on the response to TV treatment among HIV+ women. METHODS: A secondary analysis was conducted of a clinical trial which randomised HIV+/TV+ women to metronidazole (MTZ) treatment: 2 g (single-dose) versus 7 day 500 mg twice daily (multidose). BV was classified using Nugent scores from baseline Gram stains. Women were recultured for TV at test-of-cure (TOC) and again at 3 months if TV-negative at TOC. Repeat TV infection rates were compared for women with a baseline TV/BV coinfection versus baseline TV infection only, and stratified by treatment arm. RESULTS: Among 244 HIV+/TV+ women (mean age=40.3, ±9.5; 92.2% African-American), the rate of BV was 66.8%. Women with BV were more likely to report douching and ≥1 recent sex partners. HIV+ women with baseline TV/BV coinfection were more likely to be TV-positive at TOC than women with baseline TV infection only (RR 2.42 (95% CI 0.96 to 6.07; p=0.05)). When stratified by treatment arm, the association was only found in the single-dose arm (p=0.02) and not in the multidose arm (p=0.92). This interaction did not persist at 3 months. CONCLUSIONS: For HIV+/TV+ women, the rate of BV was high, and BV was associated with early failure of the MTZ single-dose treatment for TV. Biological explanations require further investigation.


Assuntos
Infecções Oportunistas Relacionadas com a AIDS/complicações , Anti-Infecciosos/administração & dosagem , Metronidazol/administração & dosagem , Vaginite por Trichomonas/tratamento farmacológico , Trichomonas vaginalis , Vaginose Bacteriana/complicações , Adulto , Relação Dose-Resposta a Droga , Feminino , Humanos , Pessoa de Meia-Idade , Recidiva , Resultado do Tratamento , Vaginite por Trichomonas/complicações
5.
Sex Transm Dis ; 37(8): 502-5, 2010 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-20502393

RESUMO

BACKGROUND: Repeat infections with Trichomonas vaginalis (TV) among human immunodeficiency virus (HIV)-infected women are common and may increase the risk of HIV transmission. Patient delivered partner treatment (PDPT) has been shown to reduce repeat infections of other sexually transmitted diseases. The purpose of this study was to evaluate adherence to PDPT and possible causes of repeat TV infection among HIV-infected women. METHODS: A multicentered cohort study was conducted in 3 US cities. Women coinfected with HIV and TV were treated with metronidazole and given treatment to deliver to all reported sex partners. A test-of-cure visit was conducted 6 to 12 days post index treatment completion and behavioral data were collected. RESULTS: Of 252 women (mean age = 40 years, s.d. 9.1) enrolled, 92.5% were black, 26.2% had CD4 cell counts <200/mm(3), 34.1% had plasma viral loads >10,000 copies, 58.3% were taking antiretrovial therapy, and 15.1% had multiple partners. Of the 183 women with partners at baseline, 75.4% provided PDPT to all partners and 61.7% reported they were sure all of their partners took the medication. Factors associated with not giving medications to all partner(s) were multiple sex partners, being single, and having at least one partner unaware of the index woman's HIV status. At test-of-cure, 10.3% were TV-positive and 16.7% reported having sex since baseline. Of the 24 repeat infections, 21 (87.5%) reported adherence to medication and no sexual exposure. CONCLUSION: HIV-infected women with TV reported high adherence to PDPT, and treatment failure was the most common probable cause of repeat infection.


Assuntos
Antiprotozoários/uso terapêutico , Infecções por HIV/complicações , Adesão à Medicação , Metronidazol/uso terapêutico , Parceiros Sexuais , Vaginite por Trichomonas/tratamento farmacológico , Vaginite por Trichomonas/prevenção & controle , Adulto , Antiprotozoários/administração & dosagem , Estudos de Coortes , Feminino , Infecções por HIV/virologia , HIV-1 , Humanos , Masculino , Metronidazol/administração & dosagem , Pessoa de Meia-Idade , Comportamento Sexual , Resultado do Tratamento , Vaginite por Trichomonas/complicações , Vaginite por Trichomonas/parasitologia , Trichomonas vaginalis/efeitos dos fármacos
7.
J Acquir Immune Defic Syndr ; 55(5): 565-71, 2010 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-21423852

RESUMO

OBJECTIVE: To determine if the metronidazole (MTZ) 2-gm single dose (recommended) is as effective as the 7-day 500 mg twice a day dose (alternative) for treatment of Trichomonas vaginalis (TV) among HIV+ women. METHODS: Phase IV randomized clinical trial; HIV+ women with culture confirmed TV were randomized to treatment arm: MTZ 2-gm single dose or MTZ 500 mg twice a day 7-day dose. All women were given 2-gm MTZ doses to deliver to their sex partners. Women were recultured for TV at a test-of-cure (TOC) visit occurring 6-12 days after treatment completion. TV-negative women at TOC were again recultured at a 3-month visit. Repeat TV infection rates were compared between arms. RESULTS: Two hundred seventy HIV+/TV+ women were enrolled (mean age = 40 years, ±9.4; 92.2% African American). Treatment arms were similar with respect to age, race, CD4 count, viral load, antiretroviral therapy status, site, and loss-to-follow up. Women in the 7-day arm had lower repeat TV infection rates at TOC [8.5% (11 of 130) versus 16.8% (21 of 125) (relative risk: 0.50, 95% confidence interval = 0.25, 1.00; P < 0.05)] and at 3 months [11.0% (8 of 73) versus 24.1% (19 of 79) (relative risk: 0.46, 95% confidence interval = 0.21, 0.98; P = 0.03)] compared with the single-dose arm. CONCLUSIONS: The 7-day MTZ dose was more effective than the single dose for the treatment of TV among HIV+ women.


Assuntos
Antitricômonas/administração & dosagem , Infecções por HIV/complicações , Metronidazol/administração & dosagem , Tricomoníase/tratamento farmacológico , Vaginite por Trichomonas/tratamento farmacológico , Trichomonas vaginalis/efeitos dos fármacos , Adulto , Antitricômonas/uso terapêutico , Contagem de Linfócito CD4 , Linfócitos T CD4-Positivos/efeitos dos fármacos , Esquema de Medicação , Feminino , Humanos , Metronidazol/uso terapêutico , Pessoa de Meia-Idade , Parceiros Sexuais , Tricomoníase/complicações , Tricomoníase/parasitologia , Vaginite por Trichomonas/complicações , Vaginite por Trichomonas/parasitologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA